Yosef Ellenbogen1,2,3, Alexander P Landry1,2,3, Leeor S Yefet1,2,3

  • 1MacFeeters Hamilton Neuro-Oncology Program, Princess Margaret Cancer Centre, University Health Network and University of Toronto, Toronto, ON, Canada.

PubMed
概括

在了解静脉瘤 (VS) 方面最近的进展揭示了关键的分子驱动因素,如NF2无活化和瘤微环境相互作用. 这种知识正在为超越手术和辐射的向治疗铺平道路.